In short
Ceritinib is an investigational drug being studied in clinical trials for the treatment of various cancers, particularly those with genetic alterations in the anaplastic lymphoma kinase (ALK) gene. This article summarizes key information from several clinical trials evaluating ceritinib's safety and efficacy in conditions like non-small cell lung cancer (NSCLC), hematologic malignancies, and other ALK-positive tumors.
At a glance
- Drug Name
- Ceritinib (also known as LDK378)
- Main Target
- ALK (Anaplastic Lymphoma Kinase) positive cancers
- Cancer Types Studied
- NSCLC, hematologic malignancies, thyroid cancer, other ALK+ solid tumors
- Common Dosing
- 750 mg orally once daily (some trials testing lower doses)
- Key Outcomes Measured
- Overall response rate, progression-free survival, safety/tolerability
- Special Populations
- Studies include patients with brain metastases and pediatric patients
- Ongoing Research
- Optimal dosing, efficacy in various ALK+ cancers, combination therapies
What is Ceritinib?
Ceritinib is a targeted cancer therapy drug. It is also known by the brand name Zykadia and the research code LDK378. Ceritinib belongs to a class of medications called ALK inhibitors. ALK stands for Anaplastic Lymphoma Kinase, which is a protein that can become abnormal in some cancer cells and drive tumor growth.
How Ceritinib Works
Ceritinib works by blocking the activity of the abnormal ALK protein in cancer cells. By doing this, it can help slow down or stop the growth of tumors that are driven by ALK abnormalities. Ceritinib is considered a "targeted therapy" because it specifically targets cancer cells with ALK abnormalities, rather than affecting all rapidly dividing cells like traditional chemotherapy.
Conditions Treated with Ceritinib
Ceritinib is primarily used to treat certain types of cancers that have ALK abnormalities. These include:
- Non-small cell lung cancer (NSCLC): This is the most common type of lung cancer. Ceritinib is approved for treating ALK-positive NSCLC.
- ALK-positive tumors: This can include various types of cancers that have ALK abnormalities.
- Brain metastases: Ceritinib is being studied for its effectiveness in treating cancer that has spread to the brain.
Research is ongoing to determine if ceritinib could be effective for other types of cancers, including:
- Colorectal adenocarcinoma (a type of colon cancer)
- Cholangiocarcinoma (bile duct cancer)
- Pancreatic adenocarcinoma
- Hepatocellular adenocarcinoma (a type of liver cancer)
- Gastric adenocarcinoma (stomach cancer)
- Esophageal adenocarcinoma
How Ceritinib is Administered
Ceritinib is taken orally (by mouth) in the form of capsules or tablets. The typical dose is 750 mg once daily, though this may vary depending on the specific condition being treated and the patient's response to the medication. Some key points about taking ceritinib:
- It is usually taken on an empty stomach, at least 1 hour before or 2 hours after a meal.
- In some cases, it may be taken with a low-fat meal to reduce side effects.
- For children or patients who have difficulty swallowing, the capsule contents can be mixed with a small amount of soft food.
- Treatment typically continues until the disease progresses or side effects become unmanageable.
Effectiveness of Ceritinib
Clinical trials have shown that ceritinib can be effective in treating ALK-positive cancers, particularly in patients who have progressed on or are intolerant to other ALK inhibitors. Some measures of effectiveness include:
- Overall Response Rate (ORR): This measures the percentage of patients whose cancer shrinks or disappears after treatment.
- Progression-Free Survival (PFS): This is the length of time during and after treatment that a patient lives with the disease without it getting worse.
- Duration of Response (DOR): This is how long the response to treatment lasts.
The exact effectiveness can vary depending on the specific type of cancer and the individual patient's characteristics.
Potential Side Effects
Like all medications, ceritinib can cause side effects. Common side effects may include:
- Gastrointestinal issues (diarrhea, nausea, vomiting)
- Fatigue
- Decreased appetite
- Abdominal pain
- Liver function abnormalities
Your healthcare team will monitor you closely for side effects and may adjust your dose if needed.
Ongoing Research
Researchers continue to study ceritinib to understand its full potential. Some areas of ongoing research include:
- Combining ceritinib with other medications: For example, a study is looking at combining ceritinib with trametinib for treating melanoma.
- Using ceritinib in different types of cancers: Studies are exploring its use in cancers beyond lung cancer, such as thyroid cancer.
- Optimizing dosing: Researchers are studying different dosing schedules and whether taking ceritinib with food can improve tolerability.
If you have questions about ceritinib or whether it might be appropriate for your condition, discuss this with your healthcare provider. They can provide personalized information based on your specific medical situation.